Laquinimod
Total Payments
$4.9M
Transactions
271
Doctors
4
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $4.9M | 271 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.9M | 271 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TV5600-AP-10124 | Teva Pharmaceuticals USA, Inc. | $3.7M | 0 |
| TV5600-CNS-20007 | Teva Pharmaceuticals USA, Inc. | $530,041 | 2 |
| MS-LAQ-301E | Teva Pharmaceuticals USA, Inc. | $270,451 | 1 |
| LAQ-MS-305 | Teva Pharmaceuticals USA, Inc. | $163,332 | 0 |
| TV5600-CNS-20006 | Teva Pharmaceuticals USA, Inc. | $144,408 | 1 |
| MS-LAQ-302E | Teva Pharmaceuticals USA, Inc. | $96,710 | 0 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $4.9M
- Total Doctors 4
- Transactions 271
About Laquinimod
Laquinimod is a drug associated with $4.9M in payments to 4 healthcare providers, recorded across 271 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2017 to 2017. In 2017, $4.9M was paid across 271 transactions to 4 doctors.
The most common payment nature for Laquinimod is "Unspecified" ($4.9M, 100.0% of total).
Laquinimod is associated with 6 research studies, including "TV5600-AP-10124" ($3.7M).